SEC 13F Intelligence

Managers / Q2 2024 · view latest →

Birchview Capital, LP

CIK 0001618205 · 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON, VT, 05401 · 802-923-3826

Reported Value
$108M
Q2 2024
Positions
61
Filings on Record
39
2019–present window
Filed
Aug 13, 2024
original filing

Summary

Birchview Capital, LP reported $108M in U.S.-listed holdings across 61 positions for Q2 2024.

The portfolio is heavily concentrated: BMY alone accounts for 26.5% of reported value.

Compared with Q1 2024, the fund opened 4 new positions and exited 3.

Portfolio Metrics

Turnover
+9.0%
vs prior filed quarter
Top-10 Concentration
+67.3%
share of reported value
Largest Position
+26.5%
Bristol Myers Squibb
New / Exited
4 / 3
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $106MQ4 ’18Q1 ’19: $160MQ2 ’19: $164MQ3 ’19: $150MQ4 ’19: $138MQ4 ’19Q1 ’20: $113MQ2 ’20: $165MQ3 ’20: $150MQ4 ’20: $174MQ4 ’20Q1 ’21: $168MQ2 ’21: $167MQ3 ’21: $147MQ4 ’21: $155MQ4 ’21Q1 ’22: $139MQ2 ’22: $137MQ3 ’22: $142MQ1 ’23: $128MQ1 ’23Q3 ’23: $117MQ4 ’23: $128MQ1 ’24: $122MQ2 ’24: $108MQ2 ’24Q3 ’24: $115MQ4 ’24: $123MQ1 ’25: $115MQ2 ’25: $101MQ2 ’25Q3 ’25: $132MQ4 ’25: $171MQ1 ’26: $176Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 91.0%Other: 9.0%
  • Common Stock · 91.0% · $98M
  • Other · 9.0% · $10M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
EXMOCEXXON MOBIL CORPNEW+5.8K5.8K+$673,332$673,332
NVCRNOVOCURE LTDNEW+20.0K20.0K+$342,600$342,600
INBXINHIBRX BIOSCIENCES INCNEW+12.1K12.1K+$170,586$170,586
OMGBPOUTSET MEDICAL INCNEW+10.0K10.0K+$38,500$38,500
CSTLCASTLE BIOSCIENCES INCADDED+20.0K34.0K+$430,080$740,180
INHIBRX INCSOLD OUT−48.4K0−$2M$0
PIONEER NATURAL RESOURCES COSOLD OUT−3.8K0−$997,500$0
BCRXBIOCRYST PHARMACEUTICALS INCADDED+20.0K40.0K+$145,600$247,200

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2024

61 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BMYBRISTOL-MYERS SQUIBB COhistory →COM26.47%$29M688.2K
2BIODESIX INCCOM7.63%$8M5.39M
3ELUTELUTIA INChistory →COM7.13%$8M1.55M
4NBIXNEUROCRINE BIOSCIENCES INChistory →COM5.39%$6M42.2K
5SILK ROAD MEDICAL INCCOM3.96%$4M158.1K
6PRTAPROTHENA CORP PLChistory →SHS3.89%$4M203.6K
7ACADACADIA PHARMACEUTICALS INChistory →COM3.77%$4M250.4K
8OVVOVINTIV INChistory →COM3.22%$3M74.2K
9UTHRUNITED THERAPEUTICS CORPhistory →COM2.95%$3M10.0K
10HROWHARROW HEALTH INChistory →COM2.90%$3M150.0K
11STOKSTOKE THERAPEUTICS INChistory →COM2.63%$3M210.0K
12PHRPHREESIA INChistory →COM2.25%$2M114.7K
13CORTCORCEPT THERAPEUTICS INChistory →COM2.23%$2M74.0K
14QUIDELORTHO CORPCOM2.08%$2M67.6K
15MASIMO CORPCOM1.78%$2M15.3K
16FHTXFOGHORN THERAPEUTICS INChistory →COM1.71%$2M320.9K
17EQUITRANS MIDSTREAM CORPORATIOCOM1.60%$2M133.1K
18PTGXPROTAGONIST THERAPEUTICS INChistory →COM1.54%$2M48.0K
19AXGNAXOGEN INChistory →COM1.32%$1M197.0K
20DCGODOCGO INChistory →COM1.32%$1M460.0K
21ALKSALKERMES PLChistory →SHS1.12%$1M50.0K
22TVTXTRAVERE THERAPEUTICS INCCOM0.93%$1M122.0K
23ATECALPHATEC HOLDINGS INCCOM0.85%$919,60088.0K
24CSTLCASTLE BIOSCIENCES INCCOM0.69%$740,18034.0K
25EXMOCEXXON MOBIL CORPCOM0.62%$673,3325.8K
26PGNYPROGYNY INCCOM0.58%$629,42022.0K
27TXG10X GENOMICS INCCL A COM0.54%$583,50030.0K
28KINIKSA PHARMACEUTICALS LTDCOM0.52%$560,10030.0K
29KALVISTA PHARMACEUTICALS INCCOM0.50%$541,88046.0K
30CYTKCYTOKINETICS INCCOM0.50%$541,80010.0K
31APELLIS PHARMACEUTICALS INCCOM0.50%$537,04014.0K
32HALOHALOZYME THERAPEUTICS INCCOM0.48%$523,60010.0K
33CHRSCOHERUS BIOSCIENCES INCCOM0.43%$467,100270.0K
34KARYOPHARM THERAPEUTICS INCCOM0.38%$407,626469.8K
35ARVNARVINAS INCCOM0.37%$399,30015.0K
36SRPTSAREPTA THERAPEUTICS INCCOM0.37%$395,0002.5K
37XENEXENON PHARMACEUTICALS INCCOM0.36%$389,90010.0K
38ACCELERATE DIAGNOSTICS INCCOM0.35%$380,529325.2K
39SPRINGWORKS THERAPEUTICS INCCOM0.35%$376,70010.0K
40CGEMCULLINAN ONCOLOGY INCCOM0.32%$348,80020.0K
41NVCRNOVOCURE LTDORD SHS0.32%$342,60020.0K
42AXSMAXSOME THERAPEUTICS INCCOM0.30%$322,0004.0K
43KROSKEROS THERAPEUTICS INCCOM0.30%$319,9007.0K
44BLUEBIRD BIO INCCOM0.28%$306,283311.2K
45AMICUS THERAPEUTICS INCCOM0.26%$277,76028.0K
46BIOHAVEN PHARMACEUTICAL HOLDING CO LTDCOM0.24%$255,6397.4K
47BCRXBIOCRYST PHARMACEUTICALS INCCOM0.23%$247,20040.0K
48XNCRXENCOR INCCOM0.22%$232,83912.3K
49BIODESIX INC COM RSTCOM0.21%$228,111153.7K
50WVEWAVE LIFE SCIENCES LTDSHS0.18%$199,60040.0K
51G1 THERAPEUTICS INCCOM0.17%$182,40080.0K
52INBXINHIBRX BIOSCIENCES INCCOM0.16%$170,58612.1K
53GOSSGOSSAMER BIO INCCOM0.12%$124,483138.2K
54LQDALIQUIDIA CORPORATIONCOM0.11%$120,00010.0K
55INFLARX NVCOM0.08%$87,00050.0K
56CABACABALETTA BIO INCCOM0.07%$74,80010.0K
572SEVENTY BIO INCCOM0.06%$68,65717.8K
58VENTYX BIOSCIENCES INCCOM0.06%$66,52828.8K
59ZNTLZENTALIS PHARMACEUTICALS INCCOM0.06%$65,44016.0K
60OMGBPOUTSET MEDICAL INCCOM0.04%$38,50010.0K
61CERO THERAPEUTICS HOLDINGS INCCLASS A COM0.00%$3,87913.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$176M73May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$171M68Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$132M69Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M71Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$115M68May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$123M68Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$115M62Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$108M61Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$122M60May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$128M59Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$117M52Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023Under review54Aug 8, 202313F-HRchanges · EDGAR ↗
Q1 2023$128M55May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review57Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$142M60Nov 28, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$137M64Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$139M63May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M67Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$147M64Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$167M62Aug 10, 202113F-HRchanges · EDGAR ↗
Q1 2021$168M54May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$174M48Feb 9, 202113F-HRchanges · EDGAR ↗
Q3 2020$150M50Nov 12, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$165M51Aug 10, 202013F-HRchanges · EDGAR ↗
Q1 2020$113M46May 12, 202013F-HRchanges · EDGAR ↗
Q4 2019$138M52Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$150M50Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$164M54Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$160M54May 3, 201913F-HRchanges · EDGAR ↗
Q4 2018$106M52Feb 6, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.